Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid
Oncology
[키워드] abnormality
acute respiratory distress
Admission
affected
Anti-viral treatment
anticoagulation
ARDS
baseline
cancer patient
cancer treatment
conditions
coronavirus
Corticosteroids
cough
COVID-19
COVID-19 illness
D-dimer
diagnosed with COVID-19
Diagnosis
discharged
elevated
Fever
fibrinogen
first positive
high mortality rate
high variability
hospital
Hospitalization
hospitalized patient
Hydroxychloroquine
Immunotherapy
incidence
inflammation marker
Inflammatory
invasive
lab
lung cancer
lung cancer patient
lung cancer patients
lymphocyte
measure
Mortality
Multiple
multivariate
multivariate model
neutrophil
no difference
outcome
pandemic
Patient
patients
PCR
Pneumonia
PROTECT
Protein
receiving
risk
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 PCR
SARS-CoV-2 RT-PCR
Shortness of breath
Spain
statistically significant
symptoms onset
syndrome
targeted therapy
Tertiary
therapy
Thoracic
time
Tocilizumab
Treatment
variable
[DOI] 10.3389/fonc.2020.01777 PMC 바로가기 [Article Type] Oncology
[DOI] 10.3389/fonc.2020.01777 PMC 바로가기 [Article Type] Oncology